[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,77,101,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100384647","5-alpha-reductase-2-as-a-marker-of-resistance-to-5ari-therapy-100384647",false,"NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","Inclusion Criteria:\n\n* Male (physiological);\n* Age ≥ 50;\n* Eligible for treatment with 5ARI therapy;\n* Presence of lower urinary tract symptoms secondary to BPH;\n* Prostate size \\>40cc by digital rectal examination;\n* Absence of prostate nodule, tenderness or firmness;\n* Mildly elevated PSA's \\>1.5 ng\u002Fml and ≤ 40 ng\u002Fml;\n* Undergoing clinically indicated prostate biopsy for elevated prostate-specific antigen (PSA).\n\nExclusion Criteria:\n\n* Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);\n* Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;\n* Current urinary tract infection;\n* Previous pelvic radiation;\n* Previous treatment with demethylating drugs;\n* Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;\n* Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.","MALE","50 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.",[25,26,27,28,29,30,31,32],"Benign Prostatic Hyperplasia","Prostate Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Lower Urinary Tract Symptoms","Urinary Obstruction","Urinary Tract Disease",[34,35],"Finasteride","5 Alpha Reductase","RECRUITING","2025-10-27",{"date":39,"type":40},"2025-10-28","ACTUAL",{"date":42,"type":40},"2020-09-25",{"date":44,"type":19},"2026-11-30",{"name":46,"class":47},"Beth Israel Deaconess Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":20,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100602991","exploring-the-potential-of-robotic-telesurgery-in-remote-settings-100602991","NCT07130708","Exploring the Potential of Robotic Telesurgery in Remote Settings","Advancing Humanitarian Healthcare: Exploring the Potential of Robotic Telesurgery in Remote Settings - A Multicentric Prospective Study","Inclusion Criteria:\n\n* Age 18 - 90\n* Male or female\n* Eligible participants for this telesurgery study must have a clearly defined indication for robotic urologic surgery, specifically:\n\n  * Localized Prostate Cancer (ICD-10: C61), appropriate for robotic radical prostatectomy.\n\nOR\n\n-Benign Prostate diseases appropriate for robotic simple prostatectomy (ICD-10: N40) These diagnoses are confirmed by clinical examination, imaging, and\u002For pathology prior to surgical planning. Patients with vague or unspecified urologic conditions will be excluded to ensure the safety and appropriateness of the surgical intervention.\n\n* Primary diagnosis of urinary system disease and prostate disorders (C61 and N40.1) scheduled to undergo treatment with robotic surgery. These patients don't have access to robotic surgery in their routine and the study will give them the opportunity to have advanced technology and the gold-standard treatment with experts in the field.\n* Willing to participate in the study\n* Mentally capable of comprehending the study protocol\n\nExclusion Criteria:\n\n* Patients who, based on multidisciplinary evaluation (surgical, anesthetic, and medical), are deemed not suitable for robotic surgery due to high perioperative risk. This includes but is not limited to:\n\n  * Uncontrolled cardiovascular, pulmonary, or metabolic disease.\n  * Severe anesthetic risk classified as ASA Class IV or higher.\n* Patients enrolled in another interventional research study that may interfere with surgical safety or outcomes.\n* Patients unwilling or unable to comply with the perioperative and follow-up schedule.\n* Vulnerable populations are excluded from this study, including:\n\n  * Minors (under 18 years old)\n  * Prisoners\n  * Cognitively impaired or decisional incapacitated individuals","18 Years","90 Years",{"count":59,"type":19},10,[22],"This study involves a type of robotic surgery called telesurgery, where a highly trained surgeon performs the surgical procedure using a secure internet connection to operate on a patient in a different location. Urologists from The goal of this study is to find out how safe and effective telesurgery is when used in real hospitals. The study aims to understand how well Telesurgery works in different settings, what technical challenges might come up (like internet speed or delays), and how it can be used to train new surgeons.",[63,27],"Prostate Carcinoma",[65,66,67],"Robotic Prostatectomy","Prostate Cancer","Telesurgery","2025-08-16",{"date":70,"type":40},"2025-08-19",{"date":72,"type":40},"2025-06-14",{"date":74,"type":19},"2033-07-30",{"name":76,"class":47},"AdventHealth",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":83,"targetDuration":4,"studyType":20,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100475376","evaluation-of-the-performance-of-a-novel-prostate-biopsy-system-compared-with-standard-of-care-biopsy-needle-on-quantitative-and-qualitative-tissue-parameters-100475376","NCT05470127","Evaluation of the Performance of a Novel Prostate Biopsy System Compared With Standard of Care Biopsy Needle on Quantitative and Qualitative Tissue Parameters","Inclusion Criteria:\n\n* Adult male scheduled for prostate biopsy\n* Able to provide informed consent\n* Able and willing to provide verbal assessment of his condition 5 days post-procedure\n\nExclusion Criteria:\n\n* Unwilling to provide consent",{"count":84,"type":19},200,[22],"Currently used biopsy devices do not predictably obtain full cores of tissue and the tissue obtained is often fragmented and disrupted making it difficult for pathological review. This post-market study will assess the utility of the SUREcore biopsy needle and the coreCARE specimen retrieval device versus a standard of care biopsy needle and the typical tissue container used in urology offices and clinics today.",[27,88],"Prostate CA",[88,90],"Needle biopsy","2025-05-02",{"date":93,"type":40},"2025-05-07",{"date":95,"type":40},"2022-08-01",{"date":97,"type":19},"2025-12",{"name":99,"class":100},"Uro-1 Medical","INDUSTRY",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":15,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":20,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":48},"100588695","turp-inpatient-with-underactive-bladder-with-boo-100588695","NCT06944743","TURP Inpatient With Underactive Bladder With BOO","Predictors of Improvement Afetr Trasurtheral Resection of Prostate in Patients With Underactive Bladder and Bladder Outlet Obstruction","Inclusion Criteria:\n\n* Male patients diagnosed with BOO and UAB\n* Age ≥ 40 years.\n\nExclusion Criteria:\n\n* Patient insulin dependent diabetes\n* Patient with history of cerbrovascular stroke or hemarrage.\n* History of prior prostate surgery.\n* Urethral pathology or surgery.\n* Patient with prostate or bladder cancer.\n* Spinal and pelvic trauma or surgery.","40 Years","70 Years",{"count":111,"type":19},50,[22],"The study is for aproved that Transurtheral Resection of prostate is good for patient with underactive bladder or not.",[115,116,27],"TURP Syndrome","Retention, Urinary","2025-04-17",{"date":119,"type":40},"2025-04-25",{"date":121,"type":40},"2025-04-01",{"date":123,"type":19},"2026-04-01",{"name":125,"class":47},"Sohag University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100565020","high-resolution-diffusion-weighted-imaging-in-prostate-100565020","NCT06636747","High Resolution Diffusion Weighted Imaging in Prostate","A Comparative Study of High Resolution DWI and Conventional DWI in Prostate","Inclusion Criteria:\n\n1. Patients who underwent standard MR scanning including T2WI, cDWI , hrDWI and respective calculated apparent diffusion coefficient (ADC) maps;\n2. Complete clinical information.\n\nExclusion Criteria:\n\nMen were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa","55 Years",{"count":135,"type":19},500,"OBSERVATIONAL","hrDWI might be an alternative to cDWI for the prostate imaging.\n\n1. increase the signal-to-noise ratio and contrast-to-noise ratio, yielding high-fidelity images with less noise in general\n2. improve the diagnostic accuracy of PCa in particular than conventional DWI",[66,27],[140,141],"diffusion weighted imaging","prostate cancer","2024-10-08",{"date":144,"type":40},"2024-10-15",{"date":146,"type":40},"2023-08-01",{"date":148,"type":19},"2026-07-31",{"name":150,"class":47},"The First Affiliated Hospital with Nanjing Medical University",2]